Veradermics, Inc.

We are a dermatologist-founded, late clinical-stage biopharmaceutical company, or the Company, we, us, or our , focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Our initial focus is developing better treatments for PHL, a condition affecting approximately 50 million men and 30 million women in the United States. Current PHL treatment options are limited and therefore are consistently plagued with high rates of treatment failure, patient dissatisfaction and treatment discontinuation. Patients and healthcare providers routinely identify the following shortcomings with currently available treatment options: n Slow onset of hair growth n Inconsistent results n Insufficient density of hair growth for patient satisfaction n Tolerability issues related to hormonal, mood and cardiac side effects n Inconvenient administration n Limited FDA-approved treatment options and no FDA-approved oral options for women We are developing VDPHL01 as an oral, non-hormonal treatment for men and women with PHL to reduce the barriers to wide adoption of chronic hair loss therapy and potentially transform PHL treatment. We believe that a marketing application could initially seek approval in male patients, followed by an sNDA for female patients, or could alternatively pursue approval in both male and female patients simultaneously depending on the timing of the completion of our clinical trials.